Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104: H4 and O157: H7

International Journal of Medical Microbiology

Volumn 303, Issue 1, 2013, Pages 1-8

  Rund, Stefan A ^a   Rohde, Holger ^b   Sonnenborn, Ulrich ^c   Oelschlaeger, Tobias A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Ardeypharm GmbH   (Germany)

Author keywords

Adhesion; E. coli Nissle 1917; EHEC; O104:H4; Probiotic; Shiga toxin

Indexed keywords

SHIGA TOXIN; VIRULENCE FACTOR;

ARTICLE; BACTERIAL GROWTH; BACTERIUM ADHERENCE; CELL STRAIN CACO 2; COCULTURE; COLONY FORMING UNIT; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; ESCHERICHIA COLI O104 H4; ESCHERICHIA COLI O157; HEMOLYTIC UREMIC SYNDROME; HOST CELL; IN VITRO STUDY; MONOCULTURE; NONHUMAN; SEROTYPE;

BACTERIAL ADHESION; CACO-2 CELLS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE OUTBREAKS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EPITHELIAL CELLS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; GERMANY; HUMANS; PROBIOTICS; SHIGA TOXIN 2;

EID: 84872938769     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2012.11.006     Document Type: Article

References (51)

1. Altenhoefer A., Oswald S., Sonnenborn U., Enders C., Schulze J., Hacker J., Oelschlaeger T.A. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol. Med. Microbiol. 2004, 40:223-229.
2. Auvray F., Dilasser F., Bibbal D., Kerouredan M., Oswald E., Brugere H. French cattle is not a reservoir of the highly virulent enteroaggregative Shiga toxin-producing Escherichia coli of serotype O104:H4. Vet. Microbiol. 2012, 158:443-445.
3. Bär F., von Koschitzky H., Roblick U., Bruch H.P., Schulze L., Sonnenborn U., Böttner M., Wedel T. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol. Motil. 2009, 21:559-566. e516-e557.
4. Bettelheim K.A. The non-O157 shiga-toxigenic (verocytotoxigenic) Escherichia coli: under-rated pathogens. Crit. Rev. Microbiol. 2007, 33:67-87.
5. Bielaszewska M., Idelevich E.A., Zhang W., Bauwens A., Schaumburg F., Mellmann A., Peters G., Karch H. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob. Agents Chemother. 2012, 56:3277-3282.
6. Bielaszewska M., Mellmann A., Zhang W., Kock R., Fruth A., Bauwens A., Peters G., Karch H. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect. Dis. 2011, 11:671-676.
7. Buchholz U., Bernard H., Werber D., Böhmer M.M., Remschmidt C., Wilking H., Deleré Y., An der Heiden M., Adlhoch C., Dreesman J., Ehlers J., Ethelberg S., Faber M., Frank C., Fricke G., Greiner M., Höhle M., Ivarsson S., Jark U., Kirchner M., Koch J., Krause G., Luber P., Rosner B., Stark K., Kühne M. German outbreak of Escherichia coli O104:H4 associated with sprouts. N. Engl. J. Med. 2011, 365:1763-1770.
8. Carey C.M., Kostrzynska M., Ojha S., Thompson S. The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157:H7. J. Microbiol. Methods 2008, 73:125-132.
9. Eaton K.A., Honkala A., Auchtung T.A., Britton R.A. Probiotic Lactobacillus reuteri ameliorates disease due to enterohemorrhagic Escherichia coli in germfree mice. Infect. Immun. 2011, 79:185-191.
10. EFSA, 2011. Tracing seeds, in particular fenugreek (Trigonella foenum-graecum) seeds, in relation to the Shiga toxin-producing E. coli (STEC) O104:H4 2011 outbreaks in Germany and France. Technical Report (European Food Safety Authority).
11. Frank C., Werber D., Cramer J.P., Askar M., Faber M., an der Heiden M., Bernard H., Fruth A., Prager R., Spode A., Wadl M., Zoufaly A., Jordan S., Kemper M.J., Follin P., Müller L., King L.A., Rosner B., Buchholz U., Stark K., Krause G. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 2011, 365:1771-1780. HUS Investigation Team.
12. Fukuda S., Toh H., Hase K., Oshima K., Nakanishi Y., Yoshimura K., Tobe T., Clarke J.M., Topping D.L., Suzuki T., Taylor T.D., Itoh K., Kikuchi J., Morita H., Hattori M., Ohno H. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469:543-547.
13. Fukuda S., Toh H., Taylor T.D., Ohno H., Hattori M. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes 2012, 3:449-454.
14. Grozdanov L., Zähringer U., Blum-Oehler G., Brade L., Henne A., Knirel Y.A., Schombel U., Schulze J., Sonnenborn U., Gottschalk G., Hacker J., Rietschel E.T., Dobrindt U. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J. Bacteriol. 2002, 184:5912-5925.
15. Harrington S.M., Dudley E.G., Nataro J.P. Pathogenesis of enteroaggregative Escherichia coli infection. FEMS Microbiol. Lett. 2006, 254:12-18.
16. Henker J., Laass M., Blokhin B.M., Bolbot Y.K., Maydannik V.G., Elze M., Wolff C., Schulze J. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr. 2007, 166:311-318.
17. Henker J., Laass M.W., Blokhin B.M., Maydannik V.G., Bolbot Y.K., Elze M., Wolff C., Schreiner A., Schulze J. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr. Infect. Dis. J. 2008, 27:494-499.
18. Jansen A., Kielstein J.T. The new face of enterohaemorrhagic Escherichia coli infections. Euro Surveill. 2011, 16(25). pii=19898.
19. Karch H., Denamur E., Dobrindt U., Finlay B.B., Hengge R., Johannes L., Ron E.Z., Tonjum T., Sansonetti P.J., Vicente M. The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak. EMBO Mol. Med. 2012, 4:841-848.
20. Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2004, 20(Suppl. 4):75-78.
21. Laing C.R., Zhang Y., Gilmour M.W., Allen V., Johnson R., Thomas J.E., Gannon V.P. A comparison of Shiga-toxin 2 bacteriophage from classical enterohemorrhagic Escherichia coli serotypes and the German E. coli O104:H4 outbreak strain. PLoS ONE 2012, 7:e37362.
22. Leatham M.P., Banerjee S., Autieri S.M., Mercado-Lubo R., Conway T., Cohen P.S. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect. Immun. 2009, 77:2876-2886.
23. Mellmann A., Harmsen D., Cummings C.A., Zentz E.B., Leopold S.R., Rico A., Prior K., Szczepanowski R., Ji Y., Zhang W., McLaughlin S.F., Henkhaus J.K., Leopold B., Bielaszewska M., Prager R., Brzoska P.M., Moore R.L., Guenther S., Rothberg J.M., Karch H. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS ONE 2011, 6:e22751.
24. Möllenbrink M., Bruckschen E. Treatment of chronic constipation with physiological Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor). Med. Klin. (Munich) 1994, 89:587-593. (in German).
25. Montrose D.C., Floch M.H. Probiotics used in human studies. J. Clin. Gastroenterol. 2005, 39:469-484.
26. Mühldorfer I., Hacker J., Keusch G.T., Acheson D.W., Tschäpe H., Kane A.V., Ritter A., Oelschläger T., Donohue-Rolfe A. Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect. Immun. 1996, 64:495-502.
27. Muniesa M., Hammerl J.A., Hertwig S., Appel B., Brussow H. Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl. Environ. Microbiol. 2012, 78:4065-4073.
28. Nissle Die antagonistische Behandlung chronischer Darmstörungen mit Kolibakterien. Med. Klein 1918, 2:29-30. (in German).
29. Nougayrede J.P., Homburg S., Taieb F., Boury M., Brzuszkiewicz E., Gottschalk G., Buchrieser C., Hacker J., Dobrindt U., Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006, 313:848-851.
30. Oelschlaeger T.A. Mechanisms of probiotic actions - a review. Int. J. Med. Microbiol. 2010, 300:57-62.
31. Ohland C.L., Macnaughton W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G807-G819.
32. Okeke I.N., Wallace-Gadsden F., Simons H.R., Matthews N., Labar A.S., Hwang J., Wain J. Multi-locus sequence typing of enteroaggregative Escherichia coli isolates from Nigerian children uncovers multiple lineages. PLoS ONE 2010, 5:e14093.
33. Pacheco A.R., Sperandio V. Shiga toxin in enterohemorrhagic E. coli: regulation and novel anti-virulence strategies. Front. Cell. Infect. Microbiol. 2012, 2:81.
34. Patzer S.I., Baquero M.R., Bravo D., Moreno F., Hantke K. The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 2003, 149:2557-2570.
35. Proulx F., Turgeon J.P., Delage G., Lafleur L., Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J. Pediatr. 1992, 121:299-303.
36. Reissbrodt R., Hammes W.P., dal Bello F., Prager R., Fruth A., Hantke K., Rakin A., Starcic-Erjavec M., Williams P.H. Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol. Lett. 2009, 290:62-69.
37. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635-639.
38. RKI, 2011. Abschließende Darstellung und Bewertung der epidemiologischen Erkenntnisse im EHEC O104:H4 Ausbruch (Berlin), Abschlussbericht.
39. Rohde H., Qin J., Cui Y., Li D., Loman N.J., Hentschke M., Chen W., Pu F., Peng Y., Li J., Xi F., Li S., Li Y., Zhang Z., Yang X., Zhao M., Wang P., Guan Y., Cen Z., Zhao X., Christner M., Kobbe R., Loos S., Oh J., Yang L., Danchin A., Gao G.F., Song Y., Yang H., Wang J., Xu J., Pallen M.J., Aepfelbacher M., Yang R. Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N. Engl. J. Med. 2011, 365:718-724.
40. Schlee M., Wehkamp J., Altenhoefer A., Oelschlaeger T.A., Stange E.F., Fellermann K. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 2007, 75:2399-2407.
41. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14:1012-1018.
42. Sherman P.M., Ossa J.C., Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr. Clin. Pract. 2009, 24:10-14.
43. Smith K.E., Wilker P.R., Reiter P.L., Hedican E.B., Bender J.B., Hedberg C.W. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr. Infect. Dis. J. 2012, 31:37-41.
44. Sonnenborn U., Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917 - features of a versatile probiotic. Microb. Ecol. Health Dis. 2009, 21:122-158.
45. Strockbine N.A., Marques L.R., Newland J.W., Smith H.W., Holmes R.K., O'Brien A.D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 1986, 53:135-140.
46. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365:1073-1086.
47. Valdebenito M., Crumbliss A.L., Winkelmann G., Hantke K. Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int. J. Med. Microbiol. 2006, 296:513-520.
48. Vassiliadis G., Destoumieux-Garzon D., Lombard C., Rebuffat S., Peduzzi J. Isolation and characterization of two members of the siderophore-microcin family, microcins M and H47. Antimicrob. Agents Chemother. 2010, 54:288-297.
49. Wehkamp J., Harder J., Wehkamp K., Wehkamp-von Meissner B., Schlee M., Enders C., Sonnenborn U., Nuding S., Bengmark S., Fellermann K., Schröder J.M., Stange E.F. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. 2004, 72:5750-5758.
50. Wieler L.H., Semmler T., Eichhorn I., Antao E.M., Kinnemann B., Geue L., Karch H., Guenther S., Bethe A. No evidence of the Shiga toxin-producing E. coli O104:H4 outbreak strain or enteroaggregative E. coli (EAEC) found in cattle faeces in northern Germany, the hotspot of the 2011 HUS outbreak area. Gut Pathog. 2011, 3:17.
51. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 2000, 342:1930-1936.